Author
@MartinShkreli
grade Bx.com/MartinShkreli ↗
Shkreli is a former hedge-fund manager and biotech executive whose recent X feed includes stock-specific short theses such as QUBT, QBTS, and RGTI, and media have documented his po
trader score
+0.88
hit rate
67%
mean α
+2.56%
signals 14d
13
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 12 scored bets: 67% hit rate, +2.56% mean alpha, trader score +0.88. Their last-14d mentions, direction-adjusted, have moved +29.5% since posting (mean over 7 mentions with price data).
Recent signals13receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | · | @MartinShkreli | · | A person familiar says Vara Fund is operating normally and has not shut down or blown up. | · | tweet ↗ |
| 2026-10-15 | · | @MartinShkreli | · | Reports an unverified rumor that the Vara AI fund has blown up. | · | tweet ↗ |
| 2026-10-09 | MRNA | @MartinShkreli | -0.90 | Short MRNA and hold the position for six months. — Explicitly calls Moderna a strong six-month short. | -11.1% | tweet ↗ |
| 2026-10-09 | · | @MartinShkreli | · | Reports a 22% decline since July 1, but the affected asset appears only in unseen context. | · | tweet ↗ |
| 2026-10-06 | HGSI | @MartinShkreli | -0.25 | Uses the historical HGSI catalyst cycle to mock similarly weak follow-on narratives in AI biotech. | · | tweet ↗ |
| 2026-10-06 | · | @MartinShkreli | · | Reports an unspecified asset down 22% since July 1. | · | tweet ↗ |
| 2026-10-05 | DNA | @MartinShkreli | -0.85 | Short TWST, DNA, RXRX and other AI drug-development plays. — Explicitly recommends shorting named AI drug-development companies due to costly clinical development. | · | tweet ↗ |
| 2026-10-05 | TWST | @MartinShkreli | -0.85 | Short TWST, DNA, RXRX and other AI drug-development plays. — Explicitly recommends shorting named AI drug-development companies due to costly clinical development. | -31.7% | tweet ↗ |
| 2026-10-05 | RXRX | @MartinShkreli | -0.85 | Short TWST, DNA, RXRX and other AI drug-development plays. — Explicitly recommends shorting named AI drug-development companies due to costly clinical development. | -22.6% | tweet ↗ |
| 2026-10-05 | QTEX | @MartinShkreli | -0.80 | Dismisses QTEX as another low-quality quantum-themed company. | -9.7% | tweet ↗ |
| 2026-10-05 | RXRX | @MartinShkreli | -0.95 | RXRX is a good short. — Explicitly calls RXRX a short and argues its AI tools do not solve drug-development judgment. | -22.6% | tweet ↗ |
| 2026-10-05 | LQDA | @MartinShkreli | +0.75 | Calls the situation bullish for LQDA and expects a return to prior highs. | +54.3% | tweet ↗ |
| 2026-10-05 | LQDA | @MartinShkreli | +0.70 | Argues LQDA's FDA process is straightforward and rejects bearish claims about NDA refiling. | +54.3% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.